Stock performance snapshot

West Pharmaceutical Services (WST) has attracted fresh attention after a recent 1 day gain of 1.24%, extending to a 4.36% move over the past week and 12.69% over the past month.

Over the past 3 months, the stock shows a 3.86% total return, while the year to date figure is a 2.38% decline. On a 1 year view, the total return stands at 34.11%, in contrast with a 24.73% total return over 3 years and 15.14% over 5 years.

With the share price at $269.81 and a 12.69% 1 month share price return, recent momentum contrasts with the 2.38% year to date share price decline and mixed multi year total shareholder returns. This suggests sentiment has recently turned more positive.

If West Pharmaceutical Services has sharpened your interest in healthcare, this is a good moment to look at other drug delivery and medtech names using our 35 healthcare AI stocks

With West Pharmaceutical Services trading at $269.81, a discount to the average analyst price target of $317.46 but an intrinsic value estimate implying a premium, the key question is whether there is still a buying opportunity here or if the market is already pricing in future growth.

Most Popular Narrative: 20.3% Undervalued

With West Pharmaceutical Services last closing at $269.81 against a narrative fair value estimate of $338.57, the widely followed story assumes meaningful upside is still on the table based on how future earnings power unfolds.

The continued growth in GLP-1s, which made up about 7% of total revenues in the first quarter, and the company's ability to capitalize on significant opportunities in this market could drive revenue and earnings growth. The increase in demand and the transition to higher-margin HVP components, supported by approximately 340 Annex 1 projects, is likely to positively impact both revenue and net margins due to a favorable mix shift.

Curious how a mid single digit revenue profile can still back a premium future P/E and higher margins, while also assuming steady buybacks and a specific discount rate.

Result: Fair Value of $338.57 (UNDERVALUED)

However, investors still need to watch for softer revenue assumptions and higher perceived risk, with tariffs and demand shifts potentially pressuring margins and execution.

Another way to look at valuation

The narrative model points to West Pharmaceutical Services trading below a fair value of $338.57, yet the current P/E of 39.4x is far above both the 20.1x fair ratio and peer yardsticks around 30.9x to 38.9x. That kind of gap can signal valuation risk if expectations cool, or room for re rating if earnings outpace the crowd.

Before you lean on the earnings multiple alone, it helps to see how the market has priced similar companies over time and where the fair ratio suggests sentiment could drift from here. That way you can judge whether this rich P/E still fits your own return and risk comfort zone. See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

Does this story of rich expectations and potential upside line up with your own read of the numbers, or does it feel stretched? To stress test the optimism and see what stands out, take a closer look at the 1 key reward

Looking for more investment ideas?

If this valuation story caught your attention, do not stop here. Use the tools available to uncover fresh opportunities that could better match your goals and risk comfort.

• Target potential mispricings by scanning 58 high quality undervalued stocks that combine quality fundamentals with room for a re rating.
• Prioritize resilience by checking 71 resilient stocks with low risk scores that score well on financial strength and volatility.
• Hunt for future standouts by reviewing the screener containing 23 high quality undiscovered gems before the crowd notices them.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.